Core Viewpoint - Abivax has been admitted to the CAC Mid 60 and SBF 120 indices on Euronext Paris, enhancing its visibility and accessibility to institutional investors and index-linked funds [1][2][3]. Group 1: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the inflammatory response in patients with chronic inflammatory diseases [1][4]. - The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [4]. Group 2: Market Impact - Inclusion in the CAC Mid 60 and SBF 120 indices is expected to broaden Abivax's investor base and enhance its market presence [2]. - The decision to include Abivax in these indices reflects the financial markets' confidence in the company's strategic vision and execution capabilities [3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Abivax SA (Exact name of Registrant as specified in its charter and translation of Registrant's name into English) 7-11 boulevard Haussmann 75009 Paris, France (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40- F. Form 20-F ☒ Form 40-F ☐ 1 On September 8, 2025, Abivax SA (the "Registrant") announced its financial results as of and ...

Core Viewpoint - Abivax SA reported a significant decline in total operating income and an increase in operating loss for the first half of 2025, highlighting challenges in its financial performance while continuing to advance its clinical programs [2][3][5]. Financial Highlights - Total operating income for the first half of 2025 was €2.1 million, down from €6.8 million in the same period of 2024, representing a decrease of €4.7 million [3][5]. - Total operating expenses increased, with research and development (R&D) costs rising to €77.9 million from €64.7 million, an increase of €13.2 million [3][5]. - The operating loss for the first half of 2025 was €93.7 million, compared to €80.0 million in the first half of 2024, reflecting an increase of €13.7 million [3][5]. Cash Position - As of June 30, 2025, the company's net financial position was €(20.2) million, a decrease of €73.6 million from €53.4 million at the end of 2024 [3][5]. - Available cash and cash equivalents decreased to €60.9 million from €144.2 million, a reduction of €83.3 million [3][5]. Recent Developments - On July 28, 2025, Abivax completed a public offering that raised approximately $747.5 million (about €637.5 million) before expenses, which is expected to support its financial needs [5][6]. - The company anticipates that its existing cash and the proceeds from the public offering will fund its operations into the fourth quarter of 2027 [7]. Clinical Programs - Abivax's lead drug candidate, obefazimod, is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, indicating ongoing commitment to its therapeutic development [8].

Core Viewpoint - Abivax SA has successfully closed a public offering of 11,679,400 American Depositary Shares (ADSs), raising approximately $747.5 million, which will support its operations and clinical trials through 2027 [1][2]. Group 1: Offering Details - The public offering included the full exercise of the underwriters' option, resulting in gross proceeds of approximately $747.5 million, or €637.5 million, before expenses [1]. - Estimated net proceeds from the offering, after deducting underwriting commissions and expenses, are approximately $700.3 million, equivalent to €597.2 million [1]. - The offering was managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, with LifeSci Capital as the lead manager [3]. Group 2: Financial Outlook - The company anticipates that the net proceeds, along with existing cash and cash equivalents, will finance operations into the fourth quarter of 2027, providing a 12-month cash runway post-NDA submission for Ulcerative Colitis, contingent on positive Phase 3 trial results [2]. Group 3: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response for chronic inflammatory diseases, with its lead drug candidate, obefazimod (ABX464), currently in Phase 3 trials for ulcerative colitis [5].

Core Viewpoint - Abivax SA has successfully completed an offering of American Depositary Shares (ADSs), raising gross proceeds of approximately $747.5 million (€637.5 million) following the full exercise of the underwriters' option to purchase additional ADSs [1][2]. Group 1: Offering Details - The offering included a total of 11,679,400 ADSs, with gross proceeds of approximately $747.5 million (€637.5 million) and estimated net proceeds of around $700.3 million (€597.2 million) after deducting underwriting commissions and offering expenses [2]. - The offering price for the additional ADSs was set at $64.00 per ADS, which corresponds to €54.58 per ordinary share, reflecting a premium of 21.0% over the volume weighted average price of the ordinary shares in the preceding trading sessions [4]. Group 2: Use of Proceeds - The company intends to apply the net proceeds from the sale of the additional ADSs on a pro rata basis to the uses identified in the base offering [3]. Group 3: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases, with its lead drug candidate, obefazimod (ABX464), currently in Phase 3 clinical trials for ulcerative colitis [7].

Core Insights - Abivax (NASDAQ: ABVX) shares experienced a significant increase of 500% on July 23, 2025, due to the company achieving positive data in its clinical trials [2]. Company Analysis - Abivax is involved in the biotechnology sector and has recently reported promising results that have led to a substantial rise in its stock price [2]. - The company is part of a broader analysis service that includes a library of over 600 biotech investing articles and a model portfolio focused on small and mid-cap stocks [2].

Core Viewpoint - Abivax SA has resumed trading of its ordinary shares on Euronext Paris following a halt related to a public offering of American Depositary Shares [1][2]. Group 1: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases [3]. - The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis [3]. Group 2: Trading Information - Trading of Abivax's ordinary shares was halted on July 24, 2025, at 9:00 a.m. CEST at the company's request to facilitate a public offering in the United States [2]. - The trading resumed at 3:30 p.m. CEST on the same day [1].

Core Viewpoint - Abivax SA has announced a public offering of American Depositary Shares (ADSs) priced at $64.00 per ADS, aiming to raise approximately $650 million to support its clinical development efforts [1][9][10]. Offering Details - The offering consists of 10,156,000 ADSs, each representing one ordinary share with a nominal value of €0.01 [1]. - The offering price reflects a 21.0% premium over the volume weighted average price of the ordinary shares on Euronext Paris over the last three trading sessions prior to pricing [2]. - The offering is managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, with LifeSci Capital as the lead manager [3]. Financial Proceeds - The gross proceeds from the offering are expected to be approximately $650 million, or €554 million, before deducting expenses [9]. - If the underwriters' option to purchase additional shares is fully exercised, total gross proceeds could reach approximately $747.5 million, or €637.5 million [10]. Use of Proceeds - The company plans to use the net proceeds to fund clinical development for its lead drug candidate, obefazimod, targeting ulcerative colitis and Crohn's disease, as well as for general corporate purposes [11][16]. - Specific allocations include approximately $140 million to $185 million for ulcerative colitis, and $30 million to $65 million for Crohn's disease [16]. Closing and Lock-up - The offering is expected to close on July 28, 2025, subject to customary conditions [6]. - Company board members and executive officers are subject to a 60-day lock-up period following the final prospectus supplement [13]. Dilution Impact - The issuance of ADSs will result in a dilution of approximately 16.0% of the company's share capital on a non-diluted basis, increasing to 18.4% if the underwriters' option is exercised [14]. Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in chronic inflammatory diseases, with its lead candidate currently in Phase 3 trials for ulcerative colitis [20].

Core Points - Abivax has announced a temporary trading halt of its ordinary shares on Euronext Paris at the company's request, effective from 9:00 a.m. CEST on July 24, 2025, due to a public offering of its American Depositary Shares in the United States [1][2] - The trading suspension is expected to last until a new communication is released by the company, with trading anticipated to resume at approximately 3:30 p.m. CEST on the same day [2] Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that utilize the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases [2] - The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [2]

Core Viewpoint - Abivax SA has announced the launch of a public offering of approximately $400 million, aimed at funding its clinical development and operational needs [1][10]. Group 1: Offering Details - The public offering will consist of American Depositary Shares (ADSs), each representing one ordinary share of the company, with a nominal value of €0.01 per share [1]. - The company plans to grant underwriters a 30-day option to purchase additional ADSs, up to 15% of the total number proposed to be sold [1]. - The offering price will be determined through a book-building process, and the final amount and terms will be announced after pricing [4][7]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to be allocated as follows: approximately 23% for the development of obefazimod for Ulcerative Colitis, approximately 5% for Crohn's Disease, and about 72% for working capital and general corporate purposes [10][14]. Group 3: Company Background - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases [18]. - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [18]. Group 4: Financial Position - As of June 30, 2025, the company had cash and cash equivalents of $71.4 million, which is expected to finance its operating cash flow requirements into the fourth quarter of 2025 [9].